Financial
Latest full-year results from official filings.
FY2025 revenue $6.16bn (+6.1%); operating margin 12.9%; net income $625.0m.
Net debt $2.76bn including leases.
- Official results release · Smith & Nephew · 31 Dec 2025
Summaries are drawn from public sources and link to them. HSH does not give a risk rating: read the summary and sources and reach your own view. Unproven allegations are labelled as such. Suppliers can submit a response, which is shown alongside.
Latest full-year results from official filings.
FY2025 revenue $6.16bn (+6.1%); operating margin 12.9%; net income $625.0m.
Net debt $2.76bn including leases.
Credible news about incidents, disputes, legal action or restructuring in the last 24 months.
Nov 2026: Smith & Nephew cut its 2026 guidance, citing weaker US Orthopaedics growth, and said earlier talks with Johnson & Johnson on a possible deal involving its Orthopaedics division had ended; it is still exploring options for that division.
Data breaches, cyber incidents, regulator action and assurance status.
Feb 2026: the 0apt ransomware group claimed to have taken data from Smith & Nephew (UK), according to a threat-intelligence site; the claim is unverified and no company confirmation was found. NHS DSPT status not yet checked.
Recalls, safety notices, regulator action and clinical safety concerns.
Sep 2026: FDA Class 2 recall of an EVOS proximal tibia plate for incorrect labelling. Mar 2026: Class 2 recall of a lot of TRIGEN humeral nails made without some distal holes, which the notice says could lead to revision surgery.
Contract delivery, go-lives, terminations and disputes.
No notable NHS contract awards, terminations or customer disputes involving Smith & Nephew found in HSH's search of the last 24 months.